
Opinion|Videos|January 24, 2025
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment
2
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
3
Retina World Congress 2026: The case for earlier surgical intervention in diabetic macular edema
4
Retina World Congress 2026: Rethinking macular hole surgery without gas tamponade
5






















